New pill could replace IV treatment for bone marrow disorder
NCT ID NCT06091267
First seen Feb 01, 2026 · Last updated May 24, 2026 · Updated 20 times
Summary
This study compares an oral medication (ASTX727) to a standard IV drug (decitabine) for treating myelodysplastic syndromes (MDS), a bone marrow disorder. About 72 Chinese adults with MDS will take both treatments in a crossover design to see if the pill works as well as the IV. The goal is to find a more convenient treatment option.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital,Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
Conditions
Explore the condition pages connected to this study.